Group 1 - The industry is experiencing a clear trend of marginal improvement, with expectations for better funding conditions and sustained demand for four categories of drugs, leading to improved same-store sales [1] - The sector's valuation is at historical lows, with low institutional holdings, and there is an anticipated recovery in demand due to respiratory diseases, along with increased industry concentration driven by market clearing [1] - Long-term transformation in the industry is underway, with leading pharmacies actively conducting transformation trials since 2025, aiming to explore feasible paths by 2026 to contribute to incremental growth and valuation recovery [1] Group 2 - The Biopharmaceutical ETF (512290) tracks the CS Biomedicine Index (930726), which selects listed companies involved in biotechnology, pharmaceuticals, medical devices, and services to reflect the overall performance of the biopharmaceutical sector [1]
医药转型变革稳步推进，生物医药ETF（512290）连续5日净流入超5000万元
Mei Ri Jing Ji Xin Wen·2025-11-20 14:59